Journal
JOURNAL OF LIPID RESEARCH
Volume 50, Issue -, Pages S207-S212Publisher
ELSEVIER
DOI: 10.1194/jlr.R800074-JLR200
Keywords
endothelial; macrophage; smooth muscle cells; clinical trials
Categories
Funding
- National Institutes of Health [P01 HL30568, R01 HL064731, R01 HL084422]
- American Heart Association
- Fondation Leducq
Ask authors/readers for more resources
There is increasing evidence that oxidized phospholipids (OxPLs) play an important role in atherosclerosis. These phospholipids accumulate in human and mouse lesions. Specific OxPLs have been identified as major regulators of many cell types present in the vessel wall. In endothelial cells, >1,000 genes are regulated. Some of these genes are pro-atherogenic and others anti-atherogenic. The anti-atherogenic effects are likely important in slowing the atherogenic process. Several receptors and signaling pathways associated with OxPL action have been identified and shown to be upregulated in human lesions. A structural model of the mechanism by which specific OxPLs serve as CD36 ligands has been identified. Specific oxidized phospholipids are also present in plasma and associated with Lp(a) particles. In humans, OxPL/apolipoprotein B has been shown to be a prognostic indicator and a separate risk factor for coronary events. Levels of OxPL in plasma have been shown to be correlated with platelet activation. jlr The results of these studies suggest an important role for OxPL in all stages of atherosclerosis. Berliner, J. A., N. Leitinger, and S. Tsimikas. The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 2009. S207-S212.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available